Q2 Earnings Forecast for PBLS Issued By Lifesci Capital

Parabilis Medicines, Inc. (NASDAQ:PBLS) – Investment analysts at Lifesci Capital issued their Q2 2026 earnings per share (EPS) estimates for Parabilis Medicines in a note issued to investors on Monday, July 6th. Lifesci Capital analyst C. Zhu expects that the company will post earnings per share of $0.09 for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. Lifesci Capital also issued estimates for Parabilis Medicines’ Q3 2026 earnings at ($0.25) EPS, Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.00) EPS, Q1 2027 earnings at ($0.29) EPS, Q2 2027 earnings at ($0.30) EPS, Q3 2027 earnings at ($0.30) EPS, Q4 2027 earnings at ($0.30) EPS and FY2027 earnings at ($1.19) EPS.

A number of other research firms have also weighed in on PBLS. Evercore began coverage on shares of Parabilis Medicines in a report on Monday. They set an “outperform” rating on the stock. Bank of America initiated coverage on shares of Parabilis Medicines in a report on Monday. They set a “buy” rating and a $45.00 price target on the stock. Leerink Partners initiated coverage on shares of Parabilis Medicines in a research note on Monday. They issued an “outperform” rating and a $40.00 price objective on the stock. Guggenheim initiated coverage on Parabilis Medicines in a report on Monday. They issued a “buy” rating and a $40.00 price objective for the company. Finally, Wall Street Zen raised Parabilis Medicines to a “hold” rating in a report on Saturday, June 20th. One research analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $41.67.

Parabilis Medicines Trading Up 3.9%

Parabilis Medicines stock opened at $30.35 on Wednesday. Parabilis Medicines has a 1 year low of $24.51 and a 1 year high of $34.47.

Insider Activity at Parabilis Medicines

In related news, Director Alan Sebulsky acquired 12,500 shares of the stock in a transaction dated Thursday, June 11th. The stock was bought at an average price of $20.00 per share, for a total transaction of $250,000.00. Following the purchase, the director directly owned 12,500 shares of the company’s stock, valued at $250,000. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Guy Levy bought 500,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were bought at an average price of $20.00 per share, for a total transaction of $10,000,000.00. Following the transaction, the insider directly owned 1,027,000 shares in the company, valued at $20,540,000. This trade represents a 94.88% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 530,000 shares of company stock worth $10,723,528.

Key Parabilis Medicines News

Here are the key news stories impacting Parabilis Medicines this week:

• Positive Sentiment: Lifesci Capital upgraded Parabilis Medicines (PBLS) to Strong-Buy, signaling improved confidence in the company’s outlook. Tickerreport.com
• Positive Sentiment: Guggenheim initiated coverage with a Buy rating and a $40 price target, implying meaningful upside from current levels. Tickerreport.com
• Positive Sentiment: Bank of America started coverage with a Buy rating and a $45 price target, another bullish signal for investors. American Banking News
• Positive Sentiment: Leerink Partners also initiated coverage with an Outperform rating and a $40 price target, adding to the positive analyst momentum. American Banking News
• Positive Sentiment: Evercore began coverage with an Outperform rating, further supporting the market’s constructive view of PBLS. The Fly